The accumulation of drug-resistance mutations on combined antiretroviral regimens (ART) backbone could affect the virological efficacy of the regimen. Our aim was to assess the impact of previous drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) on the probability of virological failure (VF) in patients, under virological control, who switched to dolutegravir (DTG)+2NRTIs regimens. All HIV-1 positive drug-experienced patients who started a regimen composed by DTG+2NRTIs [abacavir/lamivudine or tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)/emtricitabine (FTC)] in the ARCA collaborative group with HIV-RNA <50 cp/mL were included in the analysis. Patients with a previous VF to integrase inhibitors were excluded. The impact of single and combined NRTIs mutations on the probability of VF (defined as 2 consecutive HIV-RNA >50 copies/mL or one HIV-RNA >1000 copies/mL) was assessed by Kaplan Meier curves. A multivariable Cox regression analysis was constructed to assess factors potentially related to VF. Five hundred and eighty-eight patients were included in the analysis with a median time of viral suppression before the switch of 37 months (IQR 12-78), of whom 148 (25.2%) had at least one previous NRTIs resistance mutation. In the multivariable model no association was observed between NRTIs mutations and VF. Conversely, the duration of viral suppression before switch resulted associated with a lower risk of VF (for 1 month increase, adjusted 0.98, 95%CI 0.96-0.99; p=0.024). Previous NRTIs mutations appeared to have no impact on the risk of VF in patients switched to DTG+2NRTIs, whereas a longer interval on a controlled viremia decreased significantly the risk of VF.
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference / A. Giacomelli, A. Lai, M. Franzetti, F. Maggiolo, S. Di Giambenedetto, V. Borghi, D. Francisci, G. Magnani, M. Pecorari, L. Monno, I. Vicenti, L. Lepore, F. Lombardi, S. Paolucci, S. Rusconi. - In: ANTIVIRAL RESEARCH. - ISSN 0166-3542. - 172(2019 Dec), p. 104635.104635.
|Titolo:||No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference|
GIACOMELLI, ANDREA (Primo) (Corresponding)
LAI, ALESSIA (Secondo)
|Parole Chiave:||Dolutegravir; Drug resistance; Genotypic resistance test; M184V/I; NNRTIs|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
Settore MED/42 - Igiene Generale e Applicata
Settore MED/07 - Microbiologia e Microbiologia Clinica
|Data di pubblicazione:||dic-2019|
|Data ahead of print / Data di stampa:||17-ott-2019|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.antiviral.2019.104635|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|No impact of previous NRTIs resistance in HIV positive patients switched to DTG.pdf||Pre-print (manoscritto inviato all'editore)||Open Access Visualizza/Apri|
|1-s2.0-S0166354219305261-main.pdf||Publisher's version/PDF||Administrator Richiedi una copia|